Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

  • ID: 3743723
  • Drug Pipelines
  • 70 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Helix BioPharma Corp.
  • LEO Pharma A/S
  • Novan, Inc.
  • MORE
Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016

Summary

‘Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2016’, provides an overview of the Genital Warts (Condylomata Acuminata) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Warts (Condylomata Acuminata), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
- The report reviews pipeline therapeutics for Genital Warts (Condylomata Acuminata) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Genital Warts (Condylomata Acuminata) therapeutics and enlists all their major and minor projects
- The report assesses Genital Warts (Condylomata Acuminata) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Genital Warts (Condylomata Acuminata)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agilvax, Inc.
  • Biogenomics Limited
  • BioMAS Ltd.
  • Helix BioPharma Corp.
  • LEO Pharma A/S
  • Novan, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Genital Warts (Condylomata Acuminata) Overview

Therapeutics Development

Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview

Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies

Genital Warts (Condylomata Acuminata) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Genital Warts (Condylomata Acuminata) - Products under Development by Companies

Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development

Agilvax, Inc.

Aviragen Therapeutics, Inc.

Biogenomics Limited

BioMAS Ltd.

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Helix BioPharma Corp.

Laboratories Ojer Pharma S.L.

LEO Pharma A/S

Novan, Inc.

Novartis AG

Tamir Biotechnology, Inc.

Zydus Cadila Healthcare Limited

Genital Warts (Condylomata Acuminata) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(cervical cancer + genital warts) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AX-03 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BTA-074 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imiquimod - Drug Profile

Product Description

Mechanism of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ingenol mebutate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

interferon alfa-2b - Drug Profile

Product Description

Mechanism of Action

R&D Progress

interferon alpha-2b (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LFX-453 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PP-210 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SB-206 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates

Genital Warts (Condylomata Acuminata) - Dormant Projects

Genital Warts (Condylomata Acuminata) - Discontinued Products

Genital Warts (Condylomata Acuminata) - Product Development Milestones

Featured News & Press Releases

Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions

Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts

Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts

Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Aviragen Therapeutics, Inc., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Biogenomics Limited, H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Laboratories Ojer Pharma S.L., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by LEO Pharma A/S, H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Novan, Inc., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Novartis AG, H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Tamir Biotechnology, Inc., H1 2016

Genital Warts (Condylomata Acuminata) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H1 2016

Genital Warts (Condylomata Acuminata) - Dormant Projects, H1 2016

Genital Warts (Condylomata Acuminata) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Genital Warts (Condylomata Acuminata), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Agilvax, Inc.
Aviragen Therapeutics, Inc.
Biogenomics Limited
BioMAS Ltd.
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Helix BioPharma Corp.
Laboratories Ojer Pharma S.L.
LEO Pharma A/S
Novan, Inc.
Novartis AG
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll